Paul Hastings advised J.P. Morgan and Leerink Partners in connection with Lexeo Therapuetics’ PIPE
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in connection with Lexeo Therapeutics’ private placement (PIPE). The PIPE consists of the sale of 6,278,905 shares of common stock at a price of $15.13 per share. Lexeo Therapeutics (Nasdaq: LXEO) is clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.
Partner and Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team, which included associate Chris Guerin.
More details can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.